棘霉素用于晚期软组织肉瘤的II期试验。一项西南肿瘤学组的研究。
Phase II trial of echinomycin in advanced soft tissue sarcomas. A Southwest Oncology Group study.
作者信息
Taylor S A, Metch B, Balcerzak S P, Hanson K H
机构信息
University of Kansas Medical Center, Kansas City.
出版信息
Invest New Drugs. 1990 Nov;8(4):381-3. doi: 10.1007/BF00198595.
PMID:2084072
Abstract
Thirty-four patients with advanced soft tissue sarcomas were entered in a phase II trial of echinomycin. Patients received 1.2 mg/m2 intravenously (i.v.) weekly times four followed by a two week rest period. There were no objective responses. Dose limiting toxicity was gastrointestinal. Echinomycin given on this weekly schedule is inactive in treating previously treated patients with advanced soft tissue sarcomas.
摘要
34例晚期软组织肉瘤患者进入了放线菌素的II期试验。患者每周静脉注射1.2mg/m²，共4次，随后休息两周。未观察到客观缓解。剂量限制性毒性为胃肠道毒性。按此每周给药方案给予放线菌素，对先前接受过治疗的晚期软组织肉瘤患者无效。
Zotero 插件